HCPLive

APRIL 5, 2024

A clinical pharmacist reviews the various pharmacological aspects of the available adalimumab biosimilars.

Pharmacology 52

Pharmacology 52

Medical Xpress - Cardiology

JANUARY 10, 2025

A research team in the Department of Pharmacology and Pharmacy, LKS Faculty of Medicine, the University of Hong Kong (HKUMed), found that hip fractures not only result in both physical and psychological injuries, but may also induce adverse cardiovascular events.

Heart Failure 64

Heart Failure Pharmacology Research 64

Cardiovascular Diabetology

JUNE 30, 2024

The available evidence on the impact of specific non-pharmacological interventions on glycaemic control is currently limited. Consequently, there is a need to determine which interventions could provide the mo.

Pharmacology 144

Pharmacology Diabetes 144

HCPLive

AUGUST 14, 2024

A key opinion leaders explore effective non-pharmacological therapies and lifestyle modifications that have shown significant promise in managing fibromyalgia symptoms, complementing traditional medication-based approaches.

Pharmacology 52

Pharmacology 52

Circulation

FEBRUARY 5, 2024

This scientific statement discusses the mechanism of arrhythmias, pharmacological treatment options, and distinct aspects of pharmacokinetics for the fetus and neonate.

Pharmacology 78

Pharmacology Arrhythmia Physiology Circulation 78

American College of Cardiology

MAY 7, 2024

The following are key points to remember about a clinical guideline from the American College of Physicians (ACP) on newer pharmacologic treatments in adults with type 2 diabetes.

Pharmacology 49

Pharmacology Diabetes Article 49

Frontiers in Cardiovascular Medicine

JULY 7, 2024

Creation of disease models utilizing hiPSCs in combination with CRISPR/Cas9 gene editing enable mechanistic insights into differential pharmacological responses. RYR2 deficient cardiomyocytes show differential pharmacological responses to L-type channel calcium inhibitors.

Pharmacology 52

Pharmacology Heart Failure Outcomes 52

Journal of Cardiothoracic Surgery

JANUARY 9, 2025

Various pharmacological and non-pharmacological methods are available t. Removing the chest tube in cardiac patients after surgery is one of the worst experiences of hospitalization in the intensive care units.

Pharmacology 105

Pharmacology Hospital Research 105

Becker's Hospital Review - Cardiology

AUGUST 27, 2024

22 in Diabetes, Obesity and Metabolism: A Journal of Pharmacology and Therapeutics. GLP-1s reduced mortality and complications from cardiovascular events, according to a study published Aug.

Pharmacology 113

Pharmacology Obesity Diabetes 113

American Heart News - Heart News

FEBRUARY 25, 2025

Statement Highlights: It is essential for health care professionals to routinely screen pregnant and postpartum women for depression and anxiety, address modifiable risk factors and consider behavioral and pharmacological interventions to improve.

Pharmacology 101

Pharmacology Risk Factors 101

Frontiers in Cardiovascular Medicine

JANUARY 28, 2025

Furthermore, we utilized mass spectrometry analysis, network pharmacology, and lipidomics to predict the potential mechanisms of FFDS in the treatment of SCHD.ResultsFollowing treatment, FFDS demonstrated significant improvements in serum triglyceride levels (P=0.013) and a reduction in the frequency of angina episodes (P=0.021).

Heart Disease 52

Heart Disease Angina Cholesterol Pharmacology 52

Med Page Today

DECEMBER 12, 2023

Preventive Services Task Force (USPSTF) plans to recommend intensive behavioral interventions -- but not pharmacologic therapies -- for kids with a high body mass index (BMI). (MedPage Today) -- The U.S. In its draft recommendation statement.

Obesity 125

Obesity BMI Pharmacology 125

Circulation

DECEMBER 3, 2024

Critical components and policy initiatives include clinicians emphasizing the prevention of tobacco product initiation and supporting cessation with established pharmacological and behavioral tobacco dependence treatment therapies as primary goals for achieving an end to commercial tobacco and nicotine addiction.

Cardiovascular Disease 73

Cardiovascular Disease Cerebrovascular Disease Pharmacology Biomarkers 73

Heart BMJ

DECEMBER 13, 2024

3 Should we continue with a conservative, stepwise approach, beginning with pharmacological management and delaying intervention until MR severity worsens? 2 As the clinical understanding of SMR evolves, so too does the debate over the optimal treatment strategy.

Pharmacology 52

Pharmacology Bicuspid/Mitral Heart Failure Outcomes 52

Journal of Cardiovascular Electrophysiology

MARCH 10, 2025

This constellation of disease states has its own unique epidemiologic features, pathophysiology, experimental and clinical mechanisms; and an increasing knowledge base with respect to clinical presentation, prognostic implications, and therapeutic options from pharmacologic advances and non-pharmacologic interventions.

Preserved Ejection Fraction 40

Preserved Ejection Fraction Atrial Fibrillation Heart Failure Pharmacology 40

Frontiers in Cardiovascular Medicine

FEBRUARY 17, 2025

Long-term management approaches for INOCA patients, including pharmacologic therapies and lifestyle interventions, are reviewed. The paper discusses a potential interference between vasodilators used in trans-radial access and coronary spasm testing.

Ischemia 52

Ischemia Angina Pharmacology Risk Factors 52

The British Journal of Cardiology

MAY 24, 2024

Optimal pharmacological and non-pharmacological management (including device treatment) have had an enormous beneficial impact on the clinical course of HF. This module will focus on lifestyle modifications and pharmacological treatment.

Pharmacology 40

Pharmacology Heart Failure 40

Frontiers in Cardiovascular Medicine

MARCH 20, 2025

The control group received conventional antiarrhythmic therapy with -blockers or propafenone, and the EECP group underwent EECP therapy in conjunction with pharmacological treatment. Patients were randomly assigned to either the control group (n=50) or the EECP group (n=50) in this randomized controlled trial.

Atrial Fibrillation 52

Atrial Fibrillation Blood Pressure Pharmacology Ultrasound 52

JAMA Cardiology

OCTOBER 26, 2024

This substudy of the Danish-German (DanGer) Shock randomized clinical trial investigates if the use of a microaxial flow pump reduces the need for pharmacological support and what the effects are on hemodynamics and lactate clearance in patients with ST-elevation myocardial infarction–induced cardiogenic shock.

Cardiogenic Shock 109

Cardiogenic Shock Myocardial Infarction Pharmacology 109

Frontiers in Cardiovascular Medicine

MARCH 12, 2024

In this narrative review, we discuss the pathophysiology of CS, novel phenotypes, evolving definitions and staging systems, currently available pharmacologic and device-based therapies, standardized, team-based management protocols, and regionalized systems-of-care aimed at improving shock outcomes.

Cardiogenic Shock 145

Cardiogenic Shock Pharmacology Outcomes Research 145

Frontiers in Cardiovascular Medicine

FEBRUARY 24, 2025

The increasing prevalence of heart failure (HF) has led to advancements in therapeutic strategies, including the development of new pharmacological treatments and the expansion of guideline recommendations across the spectrum of left ventricular ejection fractions.

Heart Failure 52

Heart Failure Heart Transplant Pharmacology Transplant 52

Open Heart

MARCH 25, 2025

Background Current pharmacological approaches for the treatment of orthostatic hypotension (OH) may detrimentally affect supine blood pressure (BP). This side effect is often unacceptable and limits the utility of medical management.

Blood Pressure 52

Blood Pressure Pharmacology Hypertension 52

Journal of Clinical Investigation - Cardiology

OCTOBER 15, 2024

Although no pharmacological interventions are yet approved for CUD, we present the most promising pharmacological interventions being tested.

Pharmacology 94

Pharmacology Innovation Risk Factors 94

HeartRhythm

FEBRUARY 8, 2025

Pharmacological treatments, including quinidine, cilostazol, and bepridil, offer alternative approaches for VF prevention, particularly for patients experiencing recurrent VF after implantable cardioverter defibrillator (ICD) implantation.1

Sudden Cardiac Death 40

Sudden Cardiac Death Pharmacology Defibrillator 40

HCPLive

SEPTEMBER 26, 2024

The FDA approves Cobenfy, the first pharmacological approach to treating schizophrenia since the 1970s.

Pharmacology 83

Pharmacology 83

Frontiers in Cardiovascular Medicine

FEBRUARY 10, 2025

Therefore, optimal secondary prevention includes managing BP through lifestyle changes and pharmacological therapy. Several modifiable risk factors, including increased blood pressure (BP), significantly contribute to cardiovascular risk in CCS.

Blood Pressure 52

Blood Pressure Pharmacology Document Risk Factors 52

Journal of Cardiovascular Pharmacology

JUNE 3, 2024

A variety of technologies, including network pharmacology, RNA-sequencing, immunohistochemistry, and Western blotting were performed to investigate its underlying mechanisms.

Pharmacology 40

Pharmacology Hypertension Technology Article 40

Journal of Clinical Investigation - Cardiology

SEPTEMBER 3, 2024

Together, these findings offer critical insights into the functional role of LSGLP-1R neurons in the physiological regulation of energy homeostasis and delineate their instrumental role in mediating the pharmacological efficacy of liraglutide.

Pharmacology 117

Pharmacology Physiology Obesity 117

HCPLive

JUNE 26, 2024

Jennifer Goldman, RPh, PharmD, discusses how the pharmacologic advancements in recent years have shifted discussion around lipid, and cardiovascular risk, management in diabetes.

Diabetes 81

Diabetes Pharmacology 81

Frontiers in Cardiovascular Medicine

FEBRUARY 20, 2024

Results Pharmacological/non-pharmacological secondary prevention methods have been efficiently applied. Baseline aggregometry indicated platelet hyperactivity, decreasing gradually and being significantly reduced late, at 12 months ( p  < 0.05).

Laboratory 111

Laboratory Pharmacology Biomarkers 111

Journal of Clinical Investigation - Cardiology

FEBRUARY 1, 2024

Pharmacologic CTH inhibition suppressed glioblastoma invasion, while CTH knockdown slowed glioblastoma invasion in vivo. A CRISPR metabolic gene screen revealed cystathionine γ-lyase (CTH), which converts cystathionine to the nonessential amino acid cysteine in the transsulfuration pathway, to be essential for glioblastoma invasion.

Pharmacology 136

Pharmacology 136

Stroke Journal

JANUARY 30, 2025

Here we tested our hypothesis that pharmacological inhibition of TGFR2 in mice models of dementia may reduce RTN gliosis, breathing disorder and cognitive impairment.We TGFR2 pharmacological inhibition additionally reduced astrogliosis in the RTN of Tg-2576 mice (drug 53.624.8 vs. 58.25.16, p=.03 03 n=7/group) and NORT (59.13.28

Pharmacology 40

Pharmacology Dementia Stroke Strokes 40

European Journal of Heart Failure

JANUARY 17, 2025

Temporal change in such biomarkers, particularly in response to pharmacological interventions and/or mechanical circulatory support, can guide management and predict outcome. Biomarkers that aid prediction and early detection of CS, provide early signs of organ dysfunction and define prognosis could help optimize management.

Cardiogenic Shock 75

Cardiogenic Shock Biomarkers Pharmacology Circulation 75

Hypertension Journal

JANUARY 2, 2024

Pharmacological inhibition of EGFR or downstream ER stress may be a promising therapeutic strategy for preventing aneurysm rupture and subarachnoid hemorrhage.

Aneurysm 45

Aneurysm Pharmacology Atherosclerosis Hemorrhage 45

Circulation

FEBRUARY 9, 2025

Circulation, Volume 151, Issue 6 , Page 400-415, February 11, 2025. Atherosclerotic cardiovascular disease is a major health concern worldwide and requires effective preventive measures.

Pharmacology 49

Pharmacology Cardiovascular Disease Plaque Risk Factors 49

DAIC

FEBRUARY 2, 2024

Optional Pre-conference Workshop to be held Friday afternoon includes a number of topics: Pharmacology 101 Pharmacology 101 – Workshop: Alana Ferrari, PharmD, BCOP How Do I Grow My Career in Cardio-Oncology? An overview of sessions, focus topics and presenters follows. Friday, February 9 Registration (1:00 - 6:00 p.m.)

Cardio Oncology 95

Cardio Oncology Cancer Pharmacology RN 95

Nature Reviews - Cardiology

JANUARY 25, 2024

Nature Reviews Cardiology, Published online: 26 January 2024; doi:10.1038/s41569-023-00986-9 In this Review, Varga and colleagues provide an overview of the evidence on immune checkpoint inhibitor-induced heart failure and cardiac dysfunction that is unrelated to myocarditis, and discuss how pharmacological targeting of immune checkpoints might be (..)

Heart Failure 84

Heart Failure Physiology Pharmacology 84